Mark and Diana Dixon Boost SkinBioTherapeutics Plc Voting Rights Above 29% Through Rock Nominees

Timeline and Details of the Shareholding Increase

SkinBioTherapeutics plc disclosed a major shareholding change following Mark H Dixon and Diana Dixon’s acquisition of voting rights. The formal notification, submitted as a Disclosure and Transparency Rule (DTR) Form TR-1, outlines the increase and the resulting shareholding held via Rock Nominees Limited, a London-registered entity. The voting rights threshold was crossed on 23 July 2026, with regulatory notification completed on 24 July 2026 in compliance with disclosure obligations for substantial shareholders.

This notification mechanism is the standard regulatory process for UK-listed companies requiring major shareholders to report changes in voting rights. The form provides detailed information on the transaction, the nominee holding structure, and identifies the ultimate beneficial owners responsible for the shares. This transparency ensures investors and the market receive timely and accurate information on significant ownership shifts and potential changes in corporate control.

Voting Rights Now Represent Nearly One-Third of SkinBioTherapeutics

Following the acquisition, Mark H Dixon and Diana Dixon hold 29.324% of SkinBioTherapeutics plc’s total voting rights, equating to 76 million ordinary shares (ISIN GB00BF33H870). This is a material increase from their previous 28.359% stake (73.5 million shares), reflecting an addition of approximately 2.5 million shares. Although the percentage increase is moderate, it signifies a growing influence within the company’s governance framework.

Holding nearly one-third of the voting rights places these shareholders in a position of substantial influence, though still below the threshold that would trigger mandatory takeover offer obligations. The notification confirms no financial instruments such as options or warrants are held that would augment voting rights. Their stake consists solely of direct ordinary shares, providing clear and immediate voting power. Investors may want to monitor whether this concentration impacts the company’s strategic decisions or capital management.

Role of Rock Nominees Limited as Shareholding Vehicle

The shares are held through Rock Nominees Limited, a London-based nominee company. Nominee arrangements are common in the UK for administrative ease, discretionary management, or privacy. Rock Nominees Limited is the registered shareholder, while Mark H Dixon and Diana Dixon are the ultimate beneficial owners responsible for the shares. The notification confirms these individuals are not controlled by any other person or entity and do not control other entities holding interests in SkinBioTherapeutics, simplifying the ownership disclosure.

Use of a nominee does not affect the substance of ownership or voting rights. Rock Nominees Limited exercises voting rights based on instructions from the Dixons. This structure is standard practice in UK-listed companies and does not indicate any unusual features of the acquisition. The Disclosure and Transparency Rules ensure that despite nominee arrangements, ultimate beneficial owners are identified, maintaining market transparency around ownership concentration.

About SkinBioTherapeutics Plc and Its Market Position

SkinBioTherapeutics plc is a UK-listed biotechnology company specializing in skin therapeutics and related biotherapeutic development. The company focuses on researching, developing, and commercializing innovative treatments for skin conditions using advanced biotherapeutic technologies. Operating under the UK Financial Conduct Authority’s regulatory framework, SkinBioTherapeutics must disclose major shareholdings and material corporate developments to protect shareholder interests.

The biotech sector, especially specialized areas like skin therapeutics, often involves long-term value creation with significant capital investment and regulatory challenges. Investors in this sector range from long-term strategic holders to institutions focused on therapeutic innovation. The increase in shareholding by Mark H Dixon and Diana Dixon may indicate confidence in the company’s pipeline or management, although no specific rationale for the acquisition is provided in the notification.

Regulatory Compliance for Major Shareholding Disclosures

This notification complies with the Financial Conduct Authority’s Disclosure and Transparency Rules (DTR), which require disclosure when voting rights cross specified thresholds (3%, 5%, 10%, 15%, 20%, 25%, 30%, 50%, and 75%). The Dixons’ combined stake of 29.324% crosses the 25% threshold, triggering the disclosure obligation. Notifications must be made promptly and within four trading days of crossing the threshold.

These rules promote market transparency and prevent undisclosed accumulation of control that could impact shareholders. The TR-1 form used provides detailed information on the transaction, shareholding structure, involved parties, and resulting voting rights. Filing with both the issuer and the FCA ensures regulatory oversight and market awareness of significant ownership changes. SkinBioTherapeutics’ announcement offers investors clear visibility of this material shift in shareholding concentration.

No Financial Instruments or Derivative Holdings Reported

The notification confirms that Mark H Dixon and Diana Dixon do not hold any financial instruments such as warrants, options, convertible securities, or derivatives that would grant additional voting rights in SkinBioTherapeutics. Sections relating to such instruments under Disclosure and Transparency Rule 5.3.1R (1) (a) and (b) report nil holdings. Their entire 29.324% stake consists of direct ordinary shares with immediate voting rights and no contingent rights from derivatives.

This straightforward shareholding structure simplifies understanding of their influence, which derives solely from direct ownership rather than complex financial arrangements. The absence of derivative positions indicates a focus on direct governance participation rather than exposure through financial engineering. This clarity benefits investors assessing the extent and nature of the Dixons’ control within the company.

Motivations Behind the Acquisition Remain Undisclosed

The notification specifies the reason as an acquisition of voting rights but does not provide details on the timing, rationale, or strategic intent behind the increase by Mark H Dixon and Diana Dixon. While the form mandates disclosure of the acquisition and resulting shareholding, it does not require explanation of underlying motivations. Investors interested in the reasons for this stake increase should watch for further announcements or filings from SkinBioTherapeutics that might clarify the strategic implications.

The incremental rise from 28.359% to 29.324% suggests ongoing accumulation, but whether this reflects a long-term investment strategy, confidence in the company’s prospects, or other factors cannot be determined from the notification alone. Investors are advised to consider the company’s regulatory news, share price trends, and fundamental data to evaluate the context of this shareholding growth. The lack of disclosed rationale highlights the importance of transparent communication from companies regarding significant shareholder changes.

Governance Impact and Shareholder Influence

Holding 29.324% of voting rights positions Mark H Dixon and Diana Dixon as the largest known shareholder group in SkinBioTherapeutics plc, granting substantial influence over shareholder resolutions including director elections, major transactions, and constitutional amendments. Their stake enables them to block ordinary resolutions if acting collectively and makes their support critical for many corporate decisions. This ownership concentration may affect minority shareholder protections, governance practices, and capital allocation policies.

The notification does not indicate whether the Dixons hold board roles or have executive influence, nor does it disclose relationships with company management. Significant ownership by insiders may align interests for long-term value creation, whereas external concentrated holdings could signal intent to influence strategy or management. Investors should monitor for announcements about related party transactions, management changes, or strategic initiatives that could clarify the implications of this increased shareholding.

Notification Completion and Regulatory Adherence

The notification was completed in London on 24 July 2026, the same day it was submitted to SkinBioTherapeutics and the FCA. This timing complies with the four trading day requirement following the 23 July 2026 threshold crossing, demonstrating adherence to Disclosure and Transparency Rules. The disclosure includes detailed information on the transaction, shareholding structure, involved parties, and confirms the absence of proxy voting or financial instruments, reflecting a comprehensive and timely filing.

The regulatory framework ensures investors receive prompt and accurate updates on ownership changes and potential shifts in corporate control. Compliance with these rules, as shown by this notification, supports informed investment decisions by providing transparency on SkinBioTherapeutics’ ownership structure. The prompt disclosure indicates commitment by both the company and the Dixons to regulatory standards and market openness. Investors should continue monitoring company announcements for further developments or strategic insights related to this ownership change.